SAN FRANCISCO, March 18, 2020 /PRNewswire/ -- NephroSant, a
startup company that is focused on redefining kidney health, today
announced the landmark publication showing high accuracy for a
urine-based assay for the surveillance of kidney transplant
patients to identify rejection.
The study was published in Science Translational Medicine and
demonstrates the assay, called QiSant, can successfully identify
both types of rejection - t-cell mediated rejection (TCMR) and
antibody mediated rejection (ABMR) - in over 600 patients with
accuracy over 95%. The study also showed the ability of QiSant
to predict rejection episodes up to 200 days before a
biopsy-confirmed rejection. Finally, the test showed the
ability to identify rejection in adult and pediatric populations,
as well as re-transplants.
"The ability to detect rejection with high sensitivity and
specificity from urine has the ability to transform the monitoring
of kidney transplant patients," said Dr. Minnie Sarwal, UCSF Professor in Residence in
Surgery and Medicine and founder of NephroSant. "Up to 20% of
kidney transplants each year are re-transplants. This
underscores the need to maximize the success of future transplants
by identifying rejection risk and manage patients in a more
proactive way," she added.
NephroSant has already published five scientific papers
looking at the performance of the assay in other areas of kidney
health, most notably in identifying Chronic Kidney Disease and
recurrence of kidney stones.
The study titled "A Urine Score for Non-Invasive Accurate
Diagnosis and Prediction of Kidney Transplant Rejection" can be
NephroSant's first product is QiSant™, which is designed
specifically for the detection of kidney transplant
rejection. The multi-biomarker QiSant™ test
generates quantitative test results from a standard urine
sample and will be marketed as a laboratory developed
test (LDT) service through NephroSant's CLIA certified
laboratory directly to hospitals and clinics caring
for kidney transplant patients.
NephroSant was founded in November
2017 by Dr. Minnie M. Sarwal,
a nephrologist, a researcher of transplant immunology and a
serial entrepreneur, as a spinout of her UCSF laboratory. Dr.
Sarwal founded NephroSant with a mission to provide noninvasive
testing solutions to assess, manage and improve global kidney
health. NephroSant plans to build on Dr. Sarwal's existing clinical
research and develop centralized lab tests and point-of-care tests
for kidney diseases and allograft monitoring for other
View original content to download